Browse by Poster Number

Type here to filter the list

Sort by#

Sort byTitle

BIOM-01

Tyrosine kinase inhibitors as a treatment of symptomatic CNS metastases in oncogene-driven NSCLC.

Favorite
BIOM-02

Identifying MGMT Alterations as biomarkers of survival in lung adenocarcinoma with brain metastases

Favorite
BIOM-03

Invasive histopathology drives poor outcomes in surgically resected brain metastases

Favorite
BIOM-04

Brain Metastasis among Female Patients Diagnosed with Stage IV Breast Cancer

Favorite
BIOM-06

Clinical and prognostic significance of KRAS mutations for brain metastases from colorectal adenocarcinoma in the United States

Favorite
BIOM-07

Expression of androgen receptor and programmed death-ligand 1 in breast-to-brain-metastases.

Favorite
BIOM-08

TargetSelector^TM cerebrospinal fluid (CSF) circulating tumor cells and biomarker analysis: improving sensitivity and targeted treatment options in breast and NSCLC cancer patients with CNS involvement

Favorite
BIOM-09

Multiplex analysis of CSF extracellular vesicles of intraspinal tumors

Favorite
BIOM-12

Circulating tumor DNA in adults with glioma: a systematic review and meta-analysis of biomarker sensitivity

Favorite
BIOM-16

Immunomic analysis of glioblastoma (GBM) using gene expression profiling

Favorite
BIOM-18

Tumor location is associated with CDKN2A status in IDH-mutant astrocytomas.

Favorite
BIOM-19

Metabolic alteration induced by selective knock down of GABPB1L in U251 cells

Favorite
BIOM-20

Proteomics Provides Potential Therapeutic Approaches to Glioblastoma Treatment: results from the Clinical Proteomics Tumor Analysis Consortium (CPTAC)

Favorite
BIOM-21

Correlation between ephrin-A2 expression and prognosis in patients with glioblastoma

Favorite
BIOM-22

Epidermal Growth Factor Receptor (EGFR) as a molecular determinant of glioblastoma response to dopamine receptor 2 (DRD2) inhibitors

Favorite
BIOM-23

Molecular profiling identifies novel biomarkers in a rural cohort of patients with glioblastoma

Favorite
BIOM-24

Identifying Vulnerability Signatures through Machine Learning in an Umbrella Trial for Glioblastoma

Favorite
BIOM-25

Identifying Extracellular Vesicles from Glioblastoma or Non-Neoplastic Cells via Imaging Flow Cytometry

Favorite
BIOM-26

Molecular predictors of response to selinexor in recurrent glioblastoma (GBM)

Favorite
BIOM-27

Predictive Evaluation of Quantitative Spatial Profiling of the Tumor Microenvironment by Multiplex Immunofluorescence in Recurrent Glioblastoma Treated with PD-1 Inhibitors

Favorite
BIOM-28

Identification of soluble AXL as a potential non-invasive serum biomarker for glioblastoma

Favorite
BIOM-29

pp65 CMV RNA Dendritic Cell Vaccine Causes Dynamic Lymph Node Volumetric Changes on MRI in Patients with Newly Diagnosed Glioblastoma

Favorite
BIOM-30

Decreased B cell and altered CD4+ T cell subset ratio predict favorable response to ruxolinitib in high-grade gliomas

Favorite
BIOM-31

Prognostic value of MGMT methylation in IDH mutant gliomas

Favorite
BIOM-32

High affinity fluorescent nanoparticles for detection IL13Rα2-positive extracellular vesicles and cells

Favorite
BIOM-33

Low Expression of DYNLT3 Predicts better prognosis for Female Glioblastoma Patients

Favorite
BIOM-34

Clinical, radiographic, and pathologic predictors of response to anti-PD-1 and anti-PD-L1 therapy in IDH-wildtype glioblastoma patients

Favorite
BIOM-36

The unique metabolomics based biomarkers of response to immunotherapy for glioblastoma

Favorite
BIOM-37

Initial radiographic assessment of ADC values in pediatric patients treated with DAY101 for recurrent or progressive low-grade gliomas (LGGs) harboring MEK/ERK pathway alterations

Favorite
BIOM-38

PI3K/AKT/mTOR signaling pathway activity in IDH-mutant diffuse glioma

Favorite
BIOM-40

Analysis of serum miRNA in glioblastoma patients: Targeted enrichment of extracellular vesicles enhances specificity for prognostic signature

Favorite
BIOM-41

Genetic markers correlated with progression-free survival times in glioblastoma patients undergoing treatment with Tumor Treating Fields

Favorite
BIOM-42

Association of Neutrophil-Lymphocyte Ratio with Glioma Grading and Survival

Favorite
BIOM-43

Glutamate receptor and glutamine metabolism profiling by gene expression analysis among patients with high grade glioma (HGG)

Favorite
BIOM-47

Longitudinal monitoring of plasma H3K27M in diffuse midline glioma patients treated with ONC201

Favorite
BIOM-48

PTEN mutations predict benefit from tumor-treating fields therapy in patients with recurrent glioblastoma

Favorite
BIOM-51

Factors associated with declining sex discrepancy in meningioma with increasing tumor aggressiveness: Retrospective review of a rural Pennsylvania cohort

Favorite
BIOM-52

A prognostic gene expression risk score for meningioma

Favorite
BIOM-53

Diffusion MR imaging derived apparent diffusion coefficient as a potential biomarker of clinical outcome in recurrent central nervous system lymphoma

Favorite
BIOM-55

DGKζ-targeted regulation of miR-34a in the proliferation and tumorigenicity of human glioblastoma

Favorite
BIOM-57

Pediatric tumor classification through genome-wide methylation profiling of extracellular vesicle DNA

Favorite
BIOM-59

TERT promoter mutation and MGMT promoter methylation-mediated sensitivity to temozolomide in IDH-wildtype glioblastoma: is there a link?

Favorite
BIOM-60

Biomarker evaluation for imipridone ONC206 reveals ClpP, ATF4, MYC, EGFR and HIF1 as key predictors of anti-cancer efficacy

Favorite
BIOM-61

Functional diagnostic testing of live-cell drug response using 3D patient derived glioblastoma spheroids on the incucyte platform

Favorite
CBIO-02

Comprehensive analysis of mechanisms and molecular targets for breast cancer leptomeningeal metastasis

Favorite
CBIO-03

ATRX loss in glioma results in epigenetic dysregulation of cell cycle phase transition

Favorite
CBIO-06

MKlp2 inhibition as a novel antimitotic for glioblastoma

Favorite
CBIO-09

Intratumoral heterogeneity of dielectric properties in glioblastoma

Favorite
CBIO-11

Novel therapy to target pr-recurrent glioma

Favorite
CBIO-13

Epigenetic deregulation of nuclear translocation - a novel mechanism for treatment resistance in glioblastoma

Favorite
CBIO-14

Elucidating the mechanism of temozolomide-induced ATR activation in MGMT-methylated glioblastoma multiforme

Favorite
CBIO-15

MDM2 inhibitor synergy with BCL-XL inhibition for p53 wild type glioblastoma

Favorite
CBIO-18

G-quadruplex stabilization targets ATRX-deficient high-grade glioma via induction of p53-independent apoptosis

Favorite
CBIO-19

Low global histone H4 acetylation levels reveal candidate quiescent cell populations in glioma and distinguish tumors by grade

Favorite
CBIO-20

Molecular mechanisms of OLIG2 transcription factor in glioblastoma

Favorite
CBIO-21

H3F3A G34R/V mutations induce chromosomal instability and promote pediatric high-grade glioma formation

Favorite
CBIO-23

Proximity-dependent biotin identification (BioID2) indicates membrane trafficking and vesicle transport as a potential novel function of extracellular signal-regulated kinase 5 (ERK5).

Favorite
COVD-02

Adapting RNA-nanoparticle vaccines from glioblastoma to SARS-CoV-2

Favorite
COVD-03

Assessing the impact of Coronavirus 19 pandemic on neuro-oncology at Guy’s Cancer Centre London

Favorite
COVD-04

Real-world perspectives: Tumor Treating Fields (TTFields) utility to optimize treatment of patients with glioblastoma (GBM) amidst COVID-19 pandemic

Favorite
COVD-08

The divided principle of justice: ethical decision-making in cancer care during the COVID-19 pandemic

Favorite
COVD-09

Investigation and Summary of Diagnosis and Treatment of Neurological Tumors During COVID-19 in China

Favorite
COVD-11

The Brain Tumor and Not for Profit and Charity Experience of Covid 19: Reacting and Adjusting to an Unprecedented Global Pandemic in the 21st Century

Favorite
COVD-13

Effects of COVID-19 pandemic on neurosurgical oncology practices at Inova Health System: An institutional experience

Favorite
COVD-14

Telemedicine Review in Neuro-Oncology: Comparative experiential analysis for Barrow Neurological Institute and Geisinger Health during the 2020 COVID-19 pandemic

Favorite
COVD-16

The COVID-19 pandemic from a neuro-oncology perspective: strategies, protocols, and lesson learned

Favorite
COVD-17

Tumor Treating Fields for glioblastoma therapy during the COVID-19 pandemic: Expert consensus on use and experience

Favorite
COVD-18

Potential to harness SARS-COV-2 neurotropism in the delivery of oncolytic virotherapy for the treatment of high-grade glioma

Favorite
COVD-19

Cognition, Cancer, and COVID: Delivering direct-to-home tele-neuropsychology services to neuro-oncology patients

Favorite
COVD-20

COVID-19 infection during chemotherapy for malignant glioma: outcomes among 3 patients

Favorite
COVD-22

COVID-19+ Glioma Patient Care: Lessons from a 5-Patient Case Series

Favorite
COVD-25

The Paradoxical Effect of COVID-19 on Cancer Care, including the Neuro-Oncology Setting

Favorite
COVD-26

Telephone consultations in neuro-oncology during the COVID-19 pandemic: levels of patient satisfaction and comparison with traditional face-to-face consultations

Favorite
COVD-27

The COVID-19 pandemic and neuro-oncological patients

Favorite
COVD-29

Continuation of temozolomide chemotherapy in a glioblastoma patient after resolution of COVID-19 pneumonia

Favorite
COVD-30

A snapshot of the impact of COVID-19 on patients with nervous system tumors.

Favorite
CSIG-01

Identification of pathogenesis-relevant microRNAs in brain metastasis

Favorite
CSIG-03

Reconciling tumor heterogeneity in glioblastoma using a pathway-based approach

Favorite
CSIG-04

Role of c-Met/β1 integrin complex in the metastatic cascade

Favorite
CSIG-06

Platelet derived growth factor receptor alpha as an oncogenic driver in Glioblastoma

Favorite
CSIG-09

ATRX deficiency in glioma impacts transcriptional profiles and the immune microenvironment in vivo

Favorite
CSIG-10

Genotype – kinome guided development of precision EGFR-targeted therapeutics for glioblastoma

Favorite
CSIG-11

Targeting PD-L1 in Glioblastoma using nanoparticle-based gene editing

Favorite
CSIG-12

HDACs-Sp1-BMI1 pathway is involved in the attenuation of stress- and therapy-induced death in glioma

Favorite
CSIG-13

TRPM7 Induces Tumorigenesis and Stemness Through Notch Activation in Glioma

Favorite
CSIG-14

Combining the glioblastoma cell membrane-permeabilizing effect of tumor treating fields (TTFields) with Withaferin A (and other) chemotherapy

Favorite
CSIG-15

Innovative computational platform addresses prostaglandin e receptor 3 as the master regulator mediating resistance to tumor treating fields in glioblastoma cells

Favorite
CSIG-16

Sexual dimporhism in iron acquisition in Glioblastoma

Favorite
CSIG-17

PRMT5 inhibition sensitizes glioblastoma models to trametinib treatment

Favorite
CSIG-20

L3MBTL3 suppresses medulloblastoma tumorigenesis through modulation of the NOTCH/RBPJ signaling pathway

Favorite
CSIG-21

BAF60C/SMARCD3 regulates tumor cell dissemination in Medulloblastoma

Favorite
CSIG-22

Cancer-associated missense single nucleotide variants regulate the stability and subcellular localization of NF2/Merlin

Favorite
CTIM-01

Glioblastoma re-irradiation: impact of concomitant chemotherapy

Favorite
CTIM-02

Two ounces of prevention: A systematic review and meta-analysis of VEGF and immune check point inhibition for primary and secondary prevention of brain metastases

Favorite
CTIM-03

Phase II study of Regorafenib in Bevacizumab refractory recurrent glioblastoma

Favorite
CTIM-04

Updates for a phase 2 open-labeled study of pembrolizumab plus TTFields plus maintenance temozolomide in patients with newly diagnosed glioblastoma (2-THE-TOP)

Favorite
CTIM-07

Identification of a baseline biomarker associated with tumor responses in a Phase I/IIa trial of a therapeutic CMV vaccine against recurrent glioblastoma (GBM)

Favorite
CTIM-08

Combination of the IMA950/Poly-ICLC Multipeptide Vaccine with Pembrolizumab in Relapsing Glioblastoma Patients

Favorite
CTIM-09

Double-Blinded, Placebo Controlled Phase 2 Study of ERC1671 in Recurrent Glioblastoma: Vaccine Overall Survival in Bevacizumab Naive and Bevacizumab Resistant Patients

Favorite
CTIM-10

Phase II Study of Pembrolizumab plus SurVaxM for glioblastoma at first recurrence

Favorite
CTIM-11

Phase I/II study to evaluate the safety and clinical efficacy of atezolizumab (atezo) in combination with temozolomide (TMZ) and radiation in patients with newly diagnosed glioblastoma (GBM)

Favorite
CTIM-15

Preliminary results of a phase II study of nivolumab with hypofractionated re-radiation and bevacizumab for recurrent MGMT methylated glioblastoma

Favorite
CTIM-16

Interstitial Photodynamic Therapy with 5-ALA for Malignant Glioma Recurrences

Favorite
CTIM-17

Phase I study of the safety and immunogenicity of personalized neoantigen vaccines and Tumor Treating Fields in patients with newly diagnosed glioblastoma

Favorite
CTIM-18

Dendritic Cell Vaccination in conjunction with Adjuvant TLR-3 Agonist administration Enhances Pro-inflammatory Immune Responses and is associated with Extended Survival in Malignant Glioma Patients

Favorite
CTIM-20

Phase I Study of Ibrutinib with Radiation and Temozolomide in Patients with Newly Diagnosed Glioblastoma

Favorite
CTIM-22

Phase 1 trial of Osimertinib with stereotactic radiosurgery (SRS) inPatients with brain metastases from EGFR positive Non-Small-Cell Lung Cancer(NSCLC)

Favorite
CTIM-23

A Phase 1 Trial of D2C7-IT in Combination with Atezolizumab in Recurrent WHO Grade IV Malignant Glioma (MG)

Favorite
CTIM-24

AUTOLOGOUS CD34+ ENRICHED HEMATOPOIETIC PROGENITOR CELLS GENETICALLY MODIFIED FOR HUMAN INTERFERON-α2, ARE WELL TOLERATED & RAPIDLY ENGRAFT IN PATIENTS WITH GLIOBLASTOMA MULTIFORME (TEM-GBM_001 STUDY)

Favorite
CTIM-26

Patient-specific dendritic cell vaccine (DC-ATA) pulsed with antigens from self-renewing autologous tumor cells in the treatment of newly-diagnosed glioblastoma: a phase II trial

Favorite
CTIM-27

Phase I/II Study of Controlled IL-12 as Immunotherapy for Diffuse Intrinsic Pontine Glioma (DIPG)

Favorite
CTIM-30

Efficacy of Pembrolizumab in Patients with Pituitary Carcinoma: results from a phase II study

Favorite
CTNI-01

Effect of stereotactic radiosurgery compared to whole-brain radiotherapy for limited brain metastasis on long term cognition and quality of life: A pooled analysis of randomized clinical trials

Favorite
CTNI-02

TBCRC049: A phase II study to assess the safety and efficacy of the combination of tucatinib, trastuzumab and capecitabine for the treatment of leptomeningeal metastasis in HER2 positive breast cancer

Favorite
CTNI-04

Activity of larotrectinib in tropomyosin receptor kinase (TRK) fusion cancer patients with central nervous system (CNS) metastases

Favorite
CTNI-08

A Phase 1-2 clinical trial of EO1001, a novel irreversible pan-ErbB inhibitor with promising brain penetration

Favorite
CTNI-09

A Phase I healthy volunteer study on the relative bioavailability and food effect of capsule and granule formulations of selumetinib

Favorite
CTNI-13

Updates on clinical outcomes and tumor recurrence patterns of a human pilot study assessing efficacy of belinostat (PXD-101) combining with chemoradiation in treating glioblastoma

Favorite
CTNI-14

A 3-Arm, Phase IIa Trial of Safety & Efficacy of Olinvacimab, a Monoclonal Antibody to VEGFR2 in Patients with Recurrent Glioblastoma Multiforme with Imaging and PK/PD assessments: Final report

Favorite
CTNI-16

Feasibility pilot study of OKN-007 in combination with adjuvant Temozolomide chemoradiotherapy in patients with newly diagnosed glioblastoma

Favorite
CTNI-20

PCV chemotherapy alone is associated with better clinical course in oligodendroglioma WHO grade II

Favorite
CTNI-21

Scalp sparing radiation with concurrent temozolomide and tumor treatment fields (SPARE) for patients with newly diagnosed glioblastoma

Favorite
CTNI-22

Retrospective analysis of the combined treatment of vincristine, ACNU, carboplatin and interferon-β plus radiotherapy (VAC-feron-R)in patients with diffuse astrocytoma

Favorite
CTNI-26

Accelerator-based BNCT in rescue treatment of patients with recurrent GBM: a multicenter phase II study

Favorite
CTNI-28

A Prospective, Observational Study Evaluating the Safety and Quality of Life of Tumor Treating Fields in Chinese Glioblastoma Patients

Favorite
CTNI-32

Phase I/II Study of Temozolomide Plus Nimustine Chemotherapy for Recurrent Malignant Gliomas: Kyoto Neuro-oncology Group

Favorite
CTNI-34

Initial analysis of phase-III trial - standard chemotherapy vs. chemotherapy guided by a cancer stem cell test in recurrent glioblastoma (NCT03632135)

Favorite
CTNI-35

Survival outcome and prognostic factors in anaplastic oligodendroglioma: a single-institution study of 95 cases

Favorite
CTNI-38

Pamiparib in combination with radiation therapy and/or temozolomide in patients with newly diagnosed or recurrent/refractory glioblastoma; phase 1b/2 final analysis

Favorite
CTNI-39

Phase 1b Clinical Trial of OKN-007 in Recurrent Malignant Glioma

Favorite
CTNI-41

Phase I Study of Ruxolitinib with Radiation and Temozolomide in Patients with Newly diagnosed Grade III Gliomas and Glioblastoma

Favorite
CTNI-42

First-in-human fluorescence guided surgery of high-grade gliomas using panitumumab-IRDye800

Favorite
CTNI-43

Anlotinib combined with STUPP regimen in treating patients with newly diagnosed glioblastoma multiforme: a phase II pilot study

Favorite
CTNI-44

Interim results of Phase 2 study to evaluate PI3K/mTOR inhibitor paxalisib (GDC-0084) given to newly diagnosed glioblastoma patients with unmethylated O₆-methylguanine-methyltransferase promoter

Favorite
CTNI-45

A phase 1b/2 clinical study of napabucasin in combination with temozolomide for adult patients with recurrent or progressed glioblastoma multiforme (GBM)

Favorite
CTNI-46

A Phase II Trial of Tumor Treating Fields (TTFields) Concomitant with Radiosurgery for the Treatment of Recurrent, Bevacizumab-naïve Glioblastoma

Favorite
CTNI-52

Phase II Study of Everolimus (Afinitor^®) for Children with Recurrent or Progressive Ependymoma

Favorite
CTNI-53

Single arm, open-label, multicenter phase II study of the radionuclide ¹⁷⁷Lu-DOTATATE (Lutathera) in adults with advanced intracranial meningioma

Favorite
CTNI-54

Long-Term Use of Everolimus plus Octreotide for Recurrent Intracranial or Spinal Meningioma: A Single Institution Experience

Favorite
CTNI-56

A phase II clinical trial using accelerator-based BNCT system for refractory recurrent high-grade meningioma

Favorite
CTNI-59

First safety analysis of anaplastic meningioma patients treated with Tumor Treating Fields (TTFields)

Favorite
CTNI-61

Pilot study of repeated planned glucarpidase following high dose methotrexate (HD-MTX) in CNS Lymphoma (CNSL)

Favorite
CTNI-64

MATRix regimen for newly diagnosed primary diffuse B-cell lymphoma of the central nervous system

Favorite
CTNI-65

Combined rituximab, methotrexate, procarbazine, vincristine, and cytarabine (R-MPV-A) treatment for patients with relapsed primary CNS lymphoma

Favorite
CTNI-66

One-year follow-up data of phase I/II study of tirabrutinib in patients with relapsed or refractory primary central nervous system lymphoma

Favorite
CTNI-68

Efficacy of TTFields in Elderly Patients with Newly Diagnosed Glioblastoma (GBM) – Sub-group Analysis of the EF-14 Trial

Favorite
CTNI-69

Precision neuro-oncology treatment guided by next generation sequencing (NGS)-based comprehensive genomic profiling: real world experience in Hong Kong

Favorite
CTNI-70

Long-term Survival in Glioblastoma Patients After Tumor Treating Fields (TTFields) Therapy

Favorite
CTNI-71

TTFields in routine clinical care of newly diagnosed GBM patients in Germany – first report on the fully enrolled TIGER study population

Favorite
CTNI-72

Phase 2 study of dianhydrogalactitol (VAL-083) in patients with MGMT-unmethylated, bevacizumab-naïve glioblastoma in the recurrent and adjuvant setting

Favorite
CTNI-73

Overall survival of newly diagnosed glioblastoma patients treated by standard therapy in comparison to standard therapy plus tumor treating fields

Favorite
CTNI-74

Pivotal TRIDENT trial: Radiation and temozolomide +/- Tumor Treating Fields in newly diagnosed glioblastoma

Favorite
CTNI-75

A pilot clinical trial of Orotecan (Val-413), a novel oral dosage formulation of irinotecan: Implications for pediatric brain tumors

Favorite
CTNI-76

Clinical Trial of VAL-083 in Newly Diagnosed MGMT-unmethylated GBM

Favorite
CTNI-78

A pediatric and young adult Phase I dose escalation safety study of BXQ-350 for refractory solid and central nervous system tumors

Favorite
CTNI-79

PriCoTTF Trial: A phase I/II trial of TTFields prior and concomitant to radiotherapy in newly diagnosed glioblastoma

Favorite
DDRE-01

Acquired and intrinsic resistance to vemurafenib in BRAF^V600E-driven melanoma brain metastases

Favorite
DDRE-02

Therapeutic targeting of brain metastasis with ERK inhibitor LY3214996 using a novel in vivo model of lung-to-brain metastasis

Favorite
DDRE-03

International preclinical drug discovery and biomarker program informing an adoptive combinatorial trial for diffuse midline gliomas

Favorite
DDRE-04

miR-149-3p inhibits the GSC phenotype and re-sensitizes therapy-resistant GBM cells

Favorite
DDRE-07

DIPG harbour alterations targetable by MEK inhibitors, with acquired resistance mechanisms overcome by combinatorial inhibition

Favorite
DDRE-09

Developing IDO-PROTACs to improve immunotherapeutic efficacy in patients with glioblastoma

Favorite
DDRE-12

PNOC001 (NCT01734512): A Phase II Study of everolimus for recurrent or progressive pediatric low-grade gliomas (pLGG)

Favorite
DDRE-14

Hemp derived extracellular vesicles (EVs): a potential anti-glioma therapy

Favorite
DDRE-15

The combination therapy of PARP inhibitor and TMZ in diffuse midline glioma harboring H3 K27M-mutant.

Favorite
DDRE-16

Synergistic tumor suppression from combination of ONC201 and epigenetic modulators EZH2 or HDAC inhibitor provides a novel treatment strategy for GBM and DMG

Favorite
DDRE-17

Initial clinical experience using osimertinib in patients with recurrent malignant gliomas with EGFR alterations

Favorite
DDRE-21

PNOC015: Phase 1 study of MTX110 delivered by Convection Enhanced Delivery (CED) in children with newly diagnosed diffuse intrinsic pontine glioma (DIPG) previously treated with radiation therapy

Favorite
DDRE-22

Novel LonP1 Inhibitors for Targeting Glioma Stem Cells

Favorite
DDRE-23

The combination PARP inhibitor olaparib with temozolomide in an experimental glioblastoma model

Favorite
DDRE-25

Novel Temozolomide Analogs to Improve Anti-Tumor Efficacy and Overcome Resistance in Glioblastoma Multiforme

Favorite
DDRE-26

Targeting the unfolded protein response potentiates marizomib antitumor activity in glioblastoma

Favorite
DDRE-30

High-Throughput Drug Screening of FDA-Approved Antineoplastic Drugs for the Treatment of Aggressive Meningiomas

Favorite
DDRE-31

Evaluation of highly potent and selective single-molecule dual EGFR/PI3K inhibitors in adult and pediatric high-grade glioma

Favorite
DDRE-32

ABC transporters restrict the brain penetration and intracranial efficacy of anticancer agents even when blood-brain barrier integrity is lost

Favorite
DDRE-33

Molecular differentiation of imipridones ONC201 and ONC206

Favorite
DDRE-34

TRIBBLES-1 (TRIB1) pseudokinase promotes survival of GBM cells by decreasing RT/TMZ induced apoptosis

Favorite
EPCO-02

Molecular Characterization of Two Novel MPNST Subgroups Identifies Therapeutic Opportunities

Favorite
EPCO-03

Report of NTRK Fusion in a Pediatric Patient with Spinal Gangliocytoma

Favorite
EPCO-04

Genomic and epigenomic hallmarks of schwannomatosis schwannomas

Favorite
EPCO-06

Molecular determinants of evolution and prognosis among diffuse lower grade astrocytomas

Favorite
EPCO-07

Leveraging Transcriptome Sequencing and Mathematical Modeling to Investigate Glioblastoma-Macrophage Interactions

Favorite
EPCO-10

Changes in alternative splicing and associated neoantigens due to therapy

Favorite
EPCO-11

In vivo functional genomic screen identifies WISP1 as an overexpressed driver of glioblastoma

Favorite
EPCO-13

Genome-wide association study in individuals of Ashkenazi Jewish ancestry identifies novel risk loci for glioma

Favorite
EPCO-16

Lactic Acid is an Epigenetic Metabolite That Drives Glioblastoma Survival and Growth

Favorite
EPCO-21

STING promoter epigenetic silencing in glioblastoma

Favorite
EPCO-22

Identifying Neoantigens for a Personalized Mutation-derived Genomic Vaccine in Patients with Newly Diagnosed Glioblastoma

Favorite
EPCO-23

Comparative Transcriptomics to Identify Targeted Therapy Candidates in High Grade Glioma

Favorite
EPCO-24

Computational approach to identifying neuroinflammation in glioblastoma multiforme (GBM)

Favorite
EPCO-28

Spheroid study of a Glioblastoma tumor identified a subclonal mutation of EGFR T790M

Favorite
EPCO-30

A radiomics based regression model to predict glioblastoma cell motility

Favorite
EPCO-34

Clinical and genetic evolution of ependymoma

Favorite
EPCO-37

Using Single-Cell RNA Sequencing to Identify Cellular Heterogeneity Within Non-functioning Pituitary Adenomas

Favorite
EPCO-38

Primary CNS diffuse large B-cell lymphoma with CIC-rearrangement identifying from pan-cancer patients excluding sarcomas

Favorite
EPID-01

Metastatic Brain Tumors in the Central Texas Military and Veteran Population

Favorite
EPID-03

Single institutional clinical and genetic analysis of metastatic prostate cancer with and without brain metastases

Favorite
EPID-04

The single center study for brain metastases of undiagnosed primary tumor and the role of surgical removal

Favorite
EPID-05

Comparative efficacy of first-line ALK-inhibitors in ALK+ lung cancer brain metastases: A network meta-analysis

Favorite
EPID-09

Quantifying social determinants of health among glioma patients

Favorite
EPID-12

Treatment Outcomes of Midline Gliomas with H3K27 M: Our Barrow Neurological Institute Experience

Favorite
EPID-13

A retrospective analysis to study the survival characteristics of patients with first progression of Glioblastoma at the Cleveland Clinic.

Favorite
EPID-14

Racial differences and disparities in patients with gliomas: a single comprehensive cancer center experience from 2008-2020

Favorite
EPID-15

Racial and socioeconomic disparities differentially affect overall and cause-specific survival in glioblastoma

Favorite
EPID-16

Epidemiological trends for longer term GBM survivors post STUPP

Favorite
EPID-17

The relationship of hormone exposure in breast cancer and subsequent risk of high grade gliomas

Favorite
EPID-18

Glioblastoma characterization in females within rural Pennsylvania: A single institutional retrospective review

Favorite
EPID-20

Novel Glioblastoma Population-based Histologic Stain Normalization

Favorite
EPID-21

Epidemiology of malignant gliomas in Korea using nationwide big data from 2007 to 2017

Favorite
EPID-23

A systemic review of central nervous system tumors in Africa from 1960 – 2017 and the need for a central brain tumor registry in Africa

Favorite
EPID-24

Obesity in males with meningioma: a U.S. population-based study

Favorite
EPID-25

Skull base meningiomas are associated with obesity in males

Favorite
EPID-26

Clinical and histological characterization of primary central nervous system sarcoma in pediatrics. A single institution experience in a middle-income country.

Favorite
EPID-28

The impact of Rituximab combination chemotherapy on the clinical outcomes of primary central nervous system lymphoma (PCNSL): An updated meta-analysis

Favorite
EPID-29

Causes of death for primary brain and CNS tumor patients in the United States (2001 – 2016): A Population based study

Favorite
EPID-30

Predictors Associated with Long-term Survivorship for Patients with Glioblastoma using the National Cancer Database (NCDB)

Favorite
EPID-31

Contemporary management of grade 2 and 3 glioma in Alberta and Manitoba, 2012-2016: Comparison of tolerability and outcomes across chemotherapy regimens

Favorite
EPID-33

Practice variation of steroid dosing and tapering schedules among the neuro-oncology community

Favorite
EPID-35

Clinical trial enrollment rate among adolescent and young adults with central nervous system tumor at Dana-Farber Cancer Institute (DFCI)

Favorite
EPID-36

Antidepressant drug use in glioblastoma patients: an epidemiological view

Favorite
EXTH-02

Tumor-homing Induced Neural Stem Cell Therapy Inhibits the Progression of Breast Cancer Brain Metastasis and Leptomeningeal Carcinomatosis

Favorite
EXTH-05

Non-cytotoxic radiation enhances delivery of antisense oligonucleotides and improves chemo-radiation efficacy in brain tumor xenografts

Favorite
EXTH-06

Integrated molecular profiling reveals targetable molecular abnormalities shared across multiple histologies of brain metastasis

Favorite
EXTH-07

Tumor-homing induced neural stem cells secreting a cytotoxic payload as an adjuvant treatment for non-small cell lung cancer brain metastases

Favorite
EXTH-09

Neo-adjuvant Temozolomide increases the efficacy of subsequent concurrent chemoradiation in a Transglutaminase-2 dependant manner

Favorite
EXTH-11

Patient Derived Induced Neural Stem Cells for Treatment of Glioblastoma

Favorite
EXTH-12

Inhibition of CBP/p300 histone acetylation activity enhances temozolomide activity in glioblastoma patient derived xenografts

Favorite
EXTH-16

Treatment of Three Different BRAF-V600E Positive Brain Tumors with Vemurafenib and Dabrafenib/Trametinib: A Case Series

Favorite
EXTH-19

Evaluating the anti-tumor effect of a noval therapeutic agent, magmas inhibitor, in malignant glioma

Favorite
EXTH-21

Intrainfusion Catheter Movement Facilitates Increased Infusate Volume Dispersed in Agarose Gel

Favorite
EXTH-22

The CNS Penetrating Taxane TPI 287 and the AURKA Inhibitor Alisertib Improve Survival In Vivo

Favorite
EXTH-23

Multivalent targeted cytolytic agents for glioblastoma treatment

Favorite
EXTH-24

Increasing therapeutic induced neural stem cell persistence in the glioblastoma tumor resection cavity

Favorite
EXTH-25

The CSF penetration of the procaspase-activating compound (PAC-1) in combination with temozolomide (TMZ) in a nonhuman primate CSF access model.

Favorite
EXTH-26

Secondary Structure Analysis of the EGFR pre-mRNA Transcript to Identify Targetable Regions and Optimize RNA Therapy

Favorite
EXTH-29

Inhibition of lysine-specific histone demethylase 1A (KDM1A/LSD1) sensitizes glioblastoma cells to chemo and radiation therapy

Favorite
EXTH-30

Expanding the utility of pre-clinical Contrast enhanced CT (CE-CT) for tumor detection in orthotopic GBM models using radiomics

Favorite
EXTH-31

Increasing Tumor Treating Fields (TTFields) efficacy by targeting the G2 cell cycle checkpoint with Wee1 or Chk1 inhibitors in glioblastoma cell lines

Favorite
EXTH-33

Valproic acid enhances the anti-proliferative effect of tumor-treating fields on patient-derived gliosarcoma cells in vitro

Favorite
EXTH-35

Synergistic Effect of Targeting Thioredoxin Reductase (TRx1) and Depletion of Glutathione System (GSH) in Glioblastoma Stem Cells

Favorite
EXTH-36

Pharmaceutical Inhibition of Cyclin Dependent Kinase 4/6 (CDK4/6) in Glioblastoma

Favorite
EXTH-38

Orthogonal in vivo models were the sole preclinical predictor of clinical efficacy in phase 1 trials of targeted therapies for glioblastoma: results of a systematic review

Favorite
EXTH-39

Hexon swapping mitigates anti-viral immune response during brain tumor virotherapy

Favorite
EXTH-40

Therapeutically targeting de novo purine biosynthesis in diffuse intrinsic pontine glioma

Favorite
EXTH-40

Therapeutically targeting de novo purine biosynthesis in diffuse intrinsic pontine glioma

Favorite
EXTH-41

The microRNA miR-138 may be responsible for some of the effects of metabolic ketosis on malignant glioma

Favorite
EXTH-43

Generation of a B-cell-based vaccine for the treatment of glioblastoma

Favorite
EXTH-44

Development of Retroviral Replicating Vectors Encoding Sequence-Optimized Nitroreductase for Prodrug Activator Gene Therapy in Human Glioma Models.

Favorite
EXTH-44

Development of Retroviral Replicating Vectors Encoding Sequence-Optimized Nitroreductase for Prodrug Activator Gene Therapy in Human Glioma Models.

Favorite
EXTH-46

Artificial intelligence-based identification of combined vandetanib and everolimus in the treatment of ACVR1-mutant diffuse intrinsic pontine glioma

Favorite
EXTH-47

Precision immunotherapy vaccines for Glioblastoma using cancer immunogenomics and selective gene enrichment strategy.

Favorite
EXTH-48

BMP4 Binding Peptide Amphiphile Nanofibers for the Treatment of Pediatric High-grade Gliomas

Favorite
EXTH-49

BXQ-350 targets to the lysosome and kills glioblastoma (GBM) cells via activation of apoptotic caspases in vitro

Favorite
EXTH-50

Activation of the Mitochondrial ClpP protease is Synthetically Lethal with HDAC1/2 Inhibition in Glioblastoma Model Systems

Favorite
EXTH-51

Anti-invasive efficacy and survival benefit of the YAP-TEAD inhibitor Verteporfin in preclinical glioblastoma models

Favorite
EXTH-52

Glioblastoma-targeting autologous induced neural stem cell therapy: evaluating safety, toxicity, persistence, and transplant methods in a post-surgical canine model

Favorite
EXTH-53

A brain-penetrant microtubule-targeting agent that disrupts hallmarks of glioma tumorigenesis

Favorite
EXTH-54

Enhanced Sensitivity of Human Glioma Cells for Temozolomide (TMZ) by Combining Therapy With Heat Shock Protein 90

Favorite
EXTH-55

PET, Image-Guided HDAC Inhibition of Pediatric Diffuse Midline Glioma Improves Survival in Murine Models

Favorite
EXTH-56

Disruption of functional networks in Glioblastoma to overcome therapy resistance

Favorite
EXTH-57

Investigation of the Tumoricidal Effects of Sonodynamic Therapy in Malignant Glioblastoma Brain Tumors

Favorite
EXTH-60

Characterization of the oncolytic adenovirus Delta-24-RGD as therapeutic agent for the treatment of the pediatric embryonal brain tumors AT/RT and CNS-PNET

Favorite
EXTH-61

Combination of Disulfiram and Copper induces NPL4 aggregation, targets CD133-Nestin cells and extends survival in Medulloblastoma Group 3 Models

Favorite
EXTH-62

Preclinical efficacy of the imipridone ONC-206 against medulloblastoma

Favorite
EXTH-63

In Vitro Drug Screening Based on in Silico Data Identifies New Therapeutic Agents for Aggressive Meningioma

Favorite
EXTH-65

Using methylation profiles to guide the repurposing of chemotherapies against high-risk meningiomas

Favorite
EXTH-66

NEO100 Transiently Opens Up the Blood Brain Barrier via Tight Junction Inhibition

Favorite
EXTH-69

Increased cancer cell permeability following Tumor Treating Fields (TTFields) application in vitro

Favorite
EXTH-70

CYP450 and metabolic profiling of anti-cancer imipridone ONC201

Favorite
EXTH-71

Cytostatic hypothermia for glioblastoma

Favorite
EXTH-72

Continuous infusion studies reveal the potency of elacridar to act as a pharmaco-enhancer for treatment of intracranial diseases by inhibiting ABCB1 and ABCG2 at the blood-brain barrier.

Favorite
EXTH-73

Heterogeneity in cell surface antigen and HLA Class I expression in pediatric brain tumors and its impact on T-cell immunotherapy

Favorite
EXTH-75

In vitro and in vivo efficacy of combinatorial inhibition of LSD1 and HDACs in patient derived glioblastoma stem cell models

Favorite
EXTH-76

The inovivo system: a novel preclinical tool for in vivo delivery of Tumor Treating Fields (TTFields)

Favorite
EXTH-77

ONC201 exhibits passive diffusion and broad distribution in the central nervous system

Favorite
IMMU-02

The survival outcomes associated with immune checkpoint inhibitors for non-small cell lung carcinoma patients with brain metastases in the United States

Favorite
IMMU-05

CSF metabolomics as a predictor of survival in patients with brain metastasis receiving immunotherapy

Favorite
IMMU-09

Concurrent dexamethasone limits the clinical benefit of immune checkpoint blockade in glioblastoma

Favorite
IMMU-13

Efficacy of CXCR6 blockade as a Potentiator of anti-PD-1 therapy for the treatment of Glioblastoma

Favorite
IMMU-15

Heparin inhibits the extracellular vesicle-mediated induction of immunosuppressive monocytes in glioblastoma

Favorite
IMMU-18

Interplay between IDH1 and ATRX mutations govern innate immune responses in gliomas

Favorite
IMMU-19

Targeting glioblastoma immunosuppression and treatment resistance with ibrutinib in combination with stereotactic radiation and immune checkpoint blockade

Favorite
IMMU-21

The combination of Delta-24-ACT with an immune checkpoint inhibitor results in anti-glioma effect and immune memory

Favorite
IMMU-23

Clinical and immunological characterization of immune checkpoint molecule LIGHT in human gliomas

Favorite
IMMU-24

Temozolomide induced immune dysfunction requires the presence of intracranial tumors

Favorite
IMMU-25

Severe and multifaceted systemic immunosuppression caused by experimental cancers of the central nervous system requires release of non-steroid soluble mediators

Favorite
IMMU-26

Unraveling antigen presentation in central nervous system anti-tumor immunity

Favorite
IMMU-28

Induction of tertiary lymphoid structure-like T-cell clusters by delivery of a novel gene combination into an immunocompetent mouse model of glioblastoma

Favorite
IMMU-29

Lag-3 compensates Tim-3 down-regulation in a human glioblastoma model

Favorite
IMMU-32

Non-Metabolic IDO Activity Increases Complement Factor H Levels Which Enhances Immunosuppression in Human Glioblastoma

Favorite
IMMU-33

Multi-antigen recognition circuits overcome challenges of specificity, heterogeneity, and durability in T-cell therapy for glioblastoma

Favorite
IMMU-42

Dual Activation of the cGAS-STING Pathway and AIM2-induced Pyroptosis by Tumor-Treating Fields Produces Anti-Tumor Immunity in Glioblastoma

Favorite
IMMU-43

Zika virus to treat glioma: turning cold tumors hot

Favorite
IMMU-44

Pre-diagnostic eosinophil level and glioblastoma development in patients with and without atopic disease

Favorite
IMMU-45

Customized lipid nanoparticles deliver nucleic acids to immune cells in brain tumors

Favorite
IMMU-46

Lineage depleted hematopoietic stem cells potentiate immune checkpoint response to anti-PD1 and anti-CD276 in murine glioma

Favorite
IMMU-47

Protein Phosphatase 2A Inhibition in NK Cell Therapy for Treatment of Medulloblastoma

Favorite
IMMU-48

CD4+ T cells restrict medulloblastoma growth and dissemination

Favorite
IMMU-49

Predicting Patient-Specific Antigens for Medulloblastoma Immunotherapy

Favorite
IMMU-51

Neurologic Immune-Related Adverse Events Mimics, Risk Factors, and Mechanisms: CLIPPERS and Aseptic Meningitis

Favorite
IMMU-52

Immune Effector Cell Associated Neurotoxicity (ICANS) among pediatric and AYA patients:MD Anderson Cancer Center experience

Favorite
INNV-04

Congenital spinal glioblastoma with sustained response to tropomyosin receptor kinase (TRK) inhibition: a case report

Favorite
INNV-05

Tumor Treating Fields (TTFields) treatment planning for a patient with astrocytoma in the spinal cord

Favorite
INNV-06

Second generation BRAF/MEK inhibition in Anaplastic Pleomorphic Xanthroastrocytoma

Favorite
INNV-10

Effects of TTFields Usage and Duration of Usage on Cellularity and Ki67 Distributions at Autopsy

Favorite
INNV-11

Glioblastoma in the Older Person – how do we decide on treatment?

Favorite
INNV-12

A single-institution retrospective review of patients with CNS tumors who initiated a ketogenic diet

Favorite
INNV-14

Utilization of a Patient Family Advisory Council to Advance Patient-Centered Care of Brain Tumor Patients

Favorite
INNV-15

Comparison of Readiband™ actigraph and associated sleep/wake classification algorithms with patient-reported sleep quality and fatigue in glioblastoma

Favorite
INNV-16

Clinical applicability of individualized drug response profiling utilizing ex-vivo tissue-derived 3D cell culture assays in high-grade glioma: a single institution case series using 3D-PREDICT results

Favorite
INNV-17

Next Generation Sequencing Impacts Outcomes in Recurrent Primary Glioblastoma: A Single-Center Retrospective Analysis

Favorite
INNV-18

Recurrent Shh medulloblastoma extraneural metastases to the bone marrow without CNS involvement

Favorite
INNV-19

Anaplastic cerebellar ependymoma in an adult female presenting with tonsillar herniation successfully treated with chemotherapy: A case report

Favorite
INNV-20

Elevated intracranial pressure without hydrocephalus in patients with neurofibromatosis 2

Favorite
INNV-21

Effective regimen of high-dose methotrexate plus temozolomide for primary central nervous system lymphoma: a single-center retrospective study

Favorite
INNV-24

The experience of fatigued brain tumour patients receiving innovative lifestyle interventions: Qualitative results from the BT-LIFE Randomised Controlled Trial.

Favorite
INNV-25

Patient centered multi-disciplinary neuro-oncologic care as directed by new patient stakeholders

Favorite
INNV-27

BT-LIFE (Brain Tumours, Lifestyle Interventions, and Fatigue Evaluation): Lessons learned from running a novel multi-sectoral research trial.

Favorite
INNV-28

Temozolomide in renal dysfunction

Favorite
INNV-29

Professional Practice Model for Advanced Practitioners in Neuro Oncology

Favorite
NCMP-01

The Role of Vascular Endothelial Growth Factor Receptor Inhibitors in Preventing Cerebral Radiation Necrosis: A Retrospective Cohort Study.

Favorite
NCMP-02

Cerebrospinal fluid (CSF) predictors of developing disseminated necrotizing leukoencephalopathy in leptomeningeal carcinomatosis (LMC): A single institutional review

Favorite
NCMP-03

Intrathecal trastuzumab treatment of her-2 positive leptomeningeal breast cancer: The University of Michigan experience.

Favorite
NCMP-04

Incidence and outcomes of brain metastases in patients with extra-pulmonary neuroendocrine neoplasms

Favorite
NCMP-05

Decoding the immune system response to leptomeningeal metastasis

Favorite
NCMP-06

Metastatic Central Nervous System Disease Secondary to Burkitt Lymphoma in a Patient with Prior History of Melanoma

Favorite
NCMP-07

Treatment-induced cerebral necrosis in gliomas: The Ohio State University Comprehensive Cancer Center (OSUCCC) experience

Favorite
NCMP-08

Efficacy of antiepileptic drugs in glioma patients with epilepsy: a systematic review.

Favorite
NCMP-09

Postmortem study of organ specific toxicity in glioblastoma patients treated with a combination of temozolomide, bevacizumab and irinotecan

Favorite
NCMP-10

IDH mutation status and the development of venous thromboembolism in astrocytoma patients

Favorite
NCMP-12

Rapidly progressive neuropathies as the sole presentation of neurolymphomatosis

Favorite
NCMP-13

Leptomeningeal disease following resection of intraventricular melanoma metastasis diagnosed through circulating tumor cells

Favorite
NCMP-14

Skull Base Osteomyelitis Due to Community-Acquired Aspergillus fumigatus Mimicking Recurrent Chondrosarcoma

Favorite
NCMP-15

CNS lymphoma: the great mimicker

Favorite
NCMP-17

Mismatch repair mutations and the central nervous system: A case series of germline mutations and CNS malignancy

Favorite
NCMP-18

Neurotoxicity as a Potential Surrogate Marker for Therapeutic Response with Commercial Anti-CD19 CAR T-cell Therapy

Favorite
NCMP-19

Side Effects from Chemotherapy versus Symptoms from COVID-19 Infection

Favorite
NCMP-20

A retrospective single-center experience with nonbacterial thrombotic endocarditis and stroke - outcomes, anticoagulation strategies, and incorporation of next-generation sequencing data

Favorite
NCMP-21

Reversible motor neuron syndrome in the setting of cancer

Favorite
NCMP-22

Second malignancies following treatment for primary central nervous system tumors in pediatric patients: a single-institutional retrospective review

Favorite
NCMP-23

Pembrolizumab-associated CD8+ vasculitic mononeuritis multiplex in a patient with mesothelioma: first case report

Favorite
NCMP-26

Recognition of paraneoplastic syndromes triggered by traditional cytotoxic cancer treatment, tumor recurrence and development of second cancer.

Favorite
NCMP-27

The use of Intravenous Immunoglobulin (IVIG) during severe neurotoxicity among the recipients of Chimeric Antigen Receptor T-cells (CAR-T) therapy.

Favorite
NCMP-28

Bevacizumab associated intracerebral hemorrhage in patients with primary CNS malignancy

Favorite
NCOG-01

Stereotactic radiosurgery for brain metastases at the Guy’s Cancer Center, London: An Audit for the first 17 months

Favorite
NCOG-03

Factors Associated with Adjacent Level Tumor Progression in Patients Receiving Separation Surgery Followed by Spine Stereotactic Radiosurgery for Metastatic Epidural Spinal Cord Compression

Favorite
NCOG-05

Management of Brain Metastasis in Triple Negative Breast Cancer

Favorite
NCOG-07

Features of Epileptogenic Brain Metastases and Their Treatment

Favorite
NCOG-08

A comparison of response-assessment and data visualization methods for characterization of time-dependent outcomes following radiosurgery (SRS) for brain metastases

Favorite
NCOG-10

ASSESSMENT OF SURVIVAL AND SAFETY FOLLOWING INTRATHECAL CHEMOTHERAPY VIA OMMAYA RESERVOIR FOR LEPTOMENINGEAL DISEASE

Favorite
NCOG-11

Post-radiosurgical outcomes of cystic vestibular schwannomas, a systematic review and meta-analysis

Favorite
NCOG-12

Stereotactic Radiosurgery for Vestibular Schwannomas in Neurofibromatosis type 2 Patients: a Systematic Review and Meta-Analysis

Favorite
NCOG-13

The impact of CME on the knowledge of neurofibromatosis type 1-related tumors

Favorite
NCOG-14

Psychosocial Outcomes in Children with Neurofibromatosis Type 1 and Plexiform Neurofibromas

Favorite
NCOG-15

Pregnancy and glioma

Favorite
NCOG-17

Predictors of survival in elderly patients undergoing surgery for GBM

Favorite
NCOG-19

Bevacizumab in real life patients with recurrent glioblastoma: benefit or futility?

Favorite
NCOG-20

Awake surgery for right frontal lobe glioma can improve the resection rate and preserve higher cognitive functions

Favorite
NCOG-21

Interim results of three cognitive rehabilitation strategies in patients with lower grade gliomas

Favorite
NCOG-23

Patterns of distress in older patients with glioblastoma: a follow-up to a single institution cross-sectional study of distress in primary brain tumor patients.

Favorite
NCOG-24

Wake Forest NCORP Research Base feasibility study of ramipril for preventing cognitive decline in glioblastoma patients receiving brain radiotherapy (WF-1801)

Favorite
NCOG-25

Efficacy of anticonvulsant therapy in glioma patients

Favorite
NCOG-26

Impact of Gender on Tumor Treating Fields Compliance in Patients with Glioblastoma

Favorite
NCOG-28

Surgery for recurrent GBM improves survival independent of prognostic factors

Favorite
NCOG-29

O⁶-methylguanine DNA methyltransferase (MGMT) promoter methylation status and the incidence of temozolomide-induced hematologic toxicity: an association study

Favorite
NCOG-30

Adjuvant versus Salvage Management for IDH-mutant Low Grade Glioma

Favorite
NCOG-33

Hematologic Predictors of Outcomes in Glioblastoma treated with Surgery and Chemoradiation

Favorite
NCOG-34

An assessment of overall survival and palliative care use among patients with gliosarcoma diagnosed over a twelve-year span

Favorite
NCOG-35

Predictors of Postoperative Seizures in Patients with Glioblastoma Multiforme

Favorite
NCOG-36

FIRST HEALTH UTILITIES OF GLIOBLASTOMA PATIENTS USING TTFIELDS TREATMENT

Favorite
NCOG-37

Natural language assessment correlates with health-related quality of life in adult glioma patients

Favorite
NCOG-39

Progression-Free and Survival Rate of Chemotherapy in Pediatrics with Optic Pathway Gliomas: A Systematic Review

Favorite
NCOG-40

Implementing RANO criteria in a resource-limited setting and its association with overall survival of glioma patients: Experience from a National Cancer Center in Indonesia

Favorite
NCOG-41

Functional outcome following non-dominant hemispheric glioma surgery from the aspect of independence level, cognitive function and return to social lives

Favorite
NCOG-42

Initial presentation and outpatient visit compliance of inmates with brain tumors.

Favorite
NCOG-43

Neurocognitive impairment and frailty in geriatric patients with high grade glioma and thoracic malignancy

Favorite
NCOG-44

Neurologic Assessment in Neuro-Oncology (NANO) scale in a phase II study of pembrolizumab or pembrolizumab plus bevacizumab in patients with recurrent glioblastoma.

Favorite
NCOG-46

A pilot study of germline coding mutations associated with impaired development and adaptive behavior in pediatric medulloblastoma patients treated on Head Start 4

Favorite
NCOG-48

Transformation from low grade meningioma and prognostic factors for shorter time to recurrence of WHO grade III meningioma diagnosis

Favorite
NCOG-51

Correlation between tumor volume and serum prolactin and impact of tumor cellular density on prolactinoma surgical outcomes in a cohort of 181 patients

Favorite
NCOG-52

Tumor Treating Fields in Meningioma

Favorite
NCOG-54

Safety of transsphenoidal surgery for nonfunctioning pituitary adenoma in elderly patients

Favorite
NCOG-55

Harmonizing language to maximize impact: an update on common data elements for meningioma and review of clinical trials in meningioma

Favorite
NCOG-57

Neuropsychological Function in Meningeal Melanocytoma: A Case Report

Favorite
NCOG-58

Impact of time from presentation to treatment initiation on clinical outcomes in central nervous system lymphoma

Favorite
NCOG-59

Progression-free survival as a primary outcome measure to compare consolidative strategies in relapsed/refractory primary CNS lymphoma.

Favorite
NCOG-60

Malignant melanoma in neurocutaneous melanocytosis: a retrospective case series (2000-2020)

Favorite
NCOG-61

A case of long term survivor of disseminated and relapsed germinoma. Eighteen years of follow up

Favorite
NCOG-62

CNS sarcoma in a toddler with novel balanced translocation of t(8;11)(q13;q13).

Favorite
NCOG-64

Incidence of early ocular complications after proton radiation for childhood brain tumors

Favorite
NCOG-66

Implication of D-Dimer in the detection of Deep Venous Thrombosis( DVT) /Pulmonary Embolism(PE) in High grade Glioma patients with out classic symptoms of DVT/PE on or off Avastin treatment.

Favorite
NCOG-68

Comparing cognitive profiles of persons with brain and non-brain metastatic cancer

Favorite
NCOG-69

Sex differences in glioblastoma patient survival as a function of extent of surgical resection and cycles of adjuvant temozolomide during standard-of-care regimens

Favorite
NCOG-71

Genome associations with neurocognitive outcomes, cerebral microbleeds (CMBs), and brain volume and white matter (WM) changes in pediatric brain tumor survivors

Favorite
NCOG-72

Differential effects of surgery and chemotherapy on children with posterior fossa brain tumors

Favorite
NCOG-73

Effect of time to diagnosis in children with malignant central nervous system tumors on survival outcomes and disease-associated morbidity: an institutional cohort study

Favorite
NCOG-75

Estimated physician cost of a neuro-oncology multidisciplinary team (MDT) tumor board meeting at a single academic center.

Favorite
NCOG-76

Baseline cognitive assessment in glioma patients with MGMT promotor methylation and/or 1p19q codeletion

Favorite
NIMG-01

MRI Virtual Biopsy and Treatment of Primary or Brain Metastatic Tumors with Targeted Nanobioconjugates

Favorite
NIMG-02

¹⁸F-Fluciclovine PET/CT to Distinguish Radiation Necrosis from Tumor Progression in Brain Metastases Treated with Stereotactic Radiosurgery

Favorite
NIMG-04

MRI evaluation of the effect of whole brain radiotherapy on brain metastasis

Favorite
NIMG-05

Advanced imaging to assess longitudinal vascular changes in brain metastases treated with checkpoint inhibition

Favorite
NIMG-06

Guillain Barre mimicking leptomeningeal spread in cancer patients: report of two cases an review of literature

Favorite
NIMG-07

Long-term follow-up of schwannoma growth behavior in adult neurofibromatosis type 2 and schwannomatosis patients using whole-body MRI

Favorite
NIMG-09

Predicting overall survival of glioblastoma patients on multi-institutional histopathology stained slides using deep learning and population-based normalization

Favorite
NIMG-10

A retrospective analysis of survival following treatment with bevacizumab in glioblastoma patients with radiographically-confirmed subependymal or leptomeningeal spread of disease

Favorite
NIMG-11

Impact of inversion time for FLAIR acquisition on the T2-FLAIR mismatch detectability for IDH-mutant, non-CODEL astrocytomas

Favorite
NIMG-12

18F-fluorethyltyrosine positron emission tomography versus magnetic resonance spectroscopy in preoperative detection of newly diagnosed gliomas by using machine learning

Favorite
NIMG-14

Machine learning-based evaluation of static and dynamic FET-PET for the detection of pseudoprogression in patients with IDH-wildtype glioblastoma

Favorite
NIMG-15

Evaluating fluctuating enhancement in oligodendrogliomas on magnetic resonance imaging

Favorite
NIMG-16

Exploratory evaluation of q-space trajectory imaging parameters as novel imaging biomarkers for gliomas

Favorite
NIMG-17

Validation of diffusion MRI as an imaging biomarker for bevacizumab therapy in recurrent glioblastoma in a randomized phase III trial of bevacizumab with or without VB-111 (GLOBE)

Favorite
NIMG-18

The clinical significance of ¹³N-NH₃, ¹⁸F-DOPA, and ¹⁸F-FDG PET/CT in the differential diagnosis between glioma recurrence and treatment effects

Favorite
NIMG-19

Using functional Ultrasound (fUS) to map brain functionality and tumor vasculature with micrometer-millisecond precision

Favorite
NIMG-22

Integration of a Radiomic Signature, Clinical variables and Plasma Cell-free DNA in Adult Patients with Newly Diagnosed Glioblastoma Predicts Patient Survival and Improves Disease Stratification

Favorite
NIMG-23

Comparison of a radio-pathomic model versus a radiology-only tumor segmentation model for the detection of infiltrative tumor in glioma patients

Favorite
NIMG-24

Glycine and glutamine by MR spectroscopy are imaging biomarkers of glioma aggressiveness

Favorite
NIMG-25

Transferrin Receptor 1 Targeted PET/CT and NIFR Probes for Imaging Glioblastoma mouse Models

Favorite
NIMG-26

Diagnosis of pseudoprogression following radiotherapy plus lomustine-temozolomide chemotherapy in newly diagnosed glioblastoma patients using FET PET

Favorite
NIMG-27

Threshold values of early metabolic changes in 1H MRSI metabolic metrics predictive for survival in patients with newly diagnosed high-grade glioma

Favorite
NIMG-29

Developing automatic segmentation method for brain tumor MR images that can be used at multiple facilities

Favorite
NIMG-30

PET IMAGING OF ANDROGEN RECEPTOR EXPRESSION IN PATIENTS WITH GBM USING [¹⁸F]-FDHT

Favorite
NIMG-31

Non-DIPG Patients Enrolled in the International DIPG Registry: Histopathologic Evaluation of Central Neuro-Imaging Review

Favorite
NIMG-32

The predictive capacity of pre-operative imaging analysis in diffuse glioma: A comparison of connectomics, radiomics, and clinical predictive models

Favorite
NIMG-33

Changes in magnetic resonance imaging after proton boost therapy for glioblastoma with and without Tumor Treating Fields therapy

Favorite
NIMG-34

Quantitative MR Parameters for the Prediction of EGFR Amplification and the TERT Promoter Mutation Status of IDH-Wildtype Lower-grade Gliomas

Favorite
NIMG-35

Improving CETCS microneedle visibility in a magnetic resonance imaging environment

Favorite
NIMG-36

Automatic stratification of enhancing and non-enhancing gliomas into genetic subtypes using deep neural networks and diffusion-weighted imaging

Favorite
NIMG-37

Delayed pseudoprogression in two patients undergoing TTFields treatment for newly diagnosed glioblastoma

Favorite
NIMG-38

Non-invasive prediction of MGMT promoter methylation using combined FET PET/MRI radiomics

Favorite
NIMG-39

Utility of Physiologic MR Metrics in Distinguishing True-progression from Pseudoprogression in Glioblastomas Stratified by MGMT Promoter Methylation

Favorite
NIMG-41

Variation in perfusion and permeability MRI depending on vascular input function selection

Favorite
NIMG-42

Horos Software for Postoperative Analysis of Pediatric High-Grade Gliomas

Favorite
NIMG-43

Imaging findings following regorafenib in patients with malignant glioma: FET PET adds valuable information to anatomical MRI

Favorite
NIMG-44

Integrating automated lesion segmentations from single-images into routine clinical workflow for volumetric response assessment

Favorite
NIMG-46

Radiogenomic features predict clinically relevant genome-wide alteration signatures in glioblastoma

Favorite
NIMG-47

Metabolic characterization of IDH mutant lower grade glioma using spectroscopic imaging optimized for 2-hydroxyglutarate detection

Favorite
NIMG-50

Initial experience: detection of aberrant hyperpolarized [1-¹³C]pyruvate metabolism in patients with GBM prior to resection

Favorite
NIMG-52

Characterization of Cognitive Function in Survivors of Diffuse Gliomas using Morphometric Correlation Networks (MCN)

Favorite
NIMG-53

Glutamate/GABA ratio on MRS is elevated in patients with lower grade gliomas and seizures

Favorite
NIMG-54

Diffuse tumor growth pattern is associated with worse outcome only in IDH wildtype but not in IDH mutant gliomas WHO II and III

Favorite
NIMG-55

A quantitative analysis of brain volume dynamics in PCNSL patients treated with high-dose methotrexate-based therapy

Favorite
NIMG-56

The Rare Case of Primary Dural Based Marginal Zone B-Cell Lymphoma Camouflaging as Mild Focal Dura Thickness and Pacymeningeal Enhancement

Favorite
NIMG-57

Association of Radiomics Based Tumor Shape Irregularity Measures and Gamma Knife Dose Planning Indices in Vestibular Schwannomas

Favorite
NIMG-58

The effect of cell confluence on the distribution of Tumor Treating Fields

Favorite
NIMG-60

Atypical posterior reversible leukoencephalopathy syndrome mimicking tumor in 1^st trimester pregnancy-'Don't believe everything you see'

Favorite
NIMG-61

Unusual Presentation of Neurosarcoidosis: a Case Series

Favorite
NIMG-62

Amphetamine-associated CNS vasculitis masquerading as tumour

Favorite
NIMG-63

The application of MRI and treatment response assessment maps (TRAMs) for monitoring treatment effects during/following proton beam therapy – initial experience

Favorite
NIMG-64

DISTINCT IMAGING PATTERNS OF PSEUDOPROGRESSION IN GLIOMA PATIENTS FOLLOWING PROTON VERSUS PHOTON RADIATION THERAPY

Favorite
NIMG-65

Study of local perturbation in computational modelling on Tumor Treating Fields (TTFields) therapy

Favorite
NIMG-66

AI-based Prognostic Imaging Biomarkers for Precision Neurooncology and the ReSPOND Consortium

Favorite
NIMG-67

Disappearing Dots – Transient Late Enhancing Lesions Years After Brain Radiotherapy

Favorite
NIMG-68

Mathematical Modeling of Thermal Damage Estimate Volumes in Magnetic Resonance-guided Laser Interstitial Thermal Therapy

Favorite
NIMG-69

Personalized Connectomic Signatures: Bridging the Gap Between Neuro-Oncology and Connectomics

Favorite
PATH-01

Brain metastases from endometrial carcinoma: tumor genetic alterations in a case series and meta-analysis

Favorite
PATH-02

Characterization of Functional Network Effects in the Cerebral Cortex During Brain Tumorigenesis in the Mouse

Favorite
PATH-04

The blood-brain barrier in diffuse midline glioma and its implications for drug delivery

Favorite
PATH-05

A retrospective study of treatment strategies and outcomes in WHO grade II and III isocitrate dehydrogenase (IDH) wild-type astrocytoma

Favorite
PATH-07

Significance of H3K4me3 in pediatric high-grade gliomas

Favorite
PATH-08

Evaluation of Mismatch Repair Gene Expression by Immunohistochemistry May Detect Early Phase of MMR deficiency in Recurrent Gliomas.

Favorite
PATH-08

Evaluation of Mismatch Repair Gene Expression by Immunohistochemistry May Detect Early Phase of MMR deficiency in Recurrent Gliomas

Favorite
PATH-10

Effects of 19q-loss in IDH-mutated astrocytomas on better prognosis and oligodendroglioma-like morphology

Favorite
PATH-16

Comprehensive genomic profiling accurately determines 1p19q codeletion status in gliomas

Favorite
PATH-17

Novel Dual Histone 3 K27M and G34R Point Mutations in a Midline Glioma

Favorite
PATH-18

A multi-center case series of adult K27M mutated diffuse midline gliomas revealing a population unique from paediatric cases.

Favorite
PATH-19

Molecular, Histologic and Clinical Characteristics of Oligodendrogliomas: A Multi-institutional Retrospective Study

Favorite
PATH-24

Detection of point mutations and gene fusions from circulating cell-free DNA (cfDNA) of glioblastoma (GBM) patients

Favorite
PATH-27

Clinical, Radiologic and Prognostic Profile of IDH wild type Diffuse Astrocytoma with Molecular Features of Glioblastoma.

Favorite
PATH-28

Extent and prognostic value of MGMT promotor methylation depend on IDH mutation and 1p19q co-deletion in glioma WHO grade II

Favorite
PATH-29

Comparative analysis of DNA methylation profiles associated with IDH-wildtype glioma and glioneuronal tumor subtypes.

Favorite
PATH-30

Clinical and Genetic Characteristics of Histone H3 K27M-mutant Diffuse Midline Gliomas in Adults

Favorite
PATH-34

Genetic profiling of aggressive meningiomas reveal diverse spectrum of accompanying alterations beyond NF2 inactivation

Favorite
PATH-36

Synchronous TTF-1-Positive tumors and pituitary adenomas. Are we sending insufficient tumor tissue for pathology?

Favorite
PATH-37

Identifying High-Risk Patients for WHO Grade I Meningioma Recurrence Using Histopathological Features and the MIB-1 Index

Favorite
PATH-38

Metastatic Meningioma Causing Chronic Respiratory Failure

Favorite
PATH-40

Intragenic DMD deletions are the most common recurrent genomic alterations in esthesioneuroblastoma

Favorite
PATH-42

Combined next generation sequencing and Immunohistochemistry in the differential diagnosis of a progressive neuronal-glial tumor: a composite neoplasm

Favorite
PATH-43

Targeted genomic analysis of primary adult brain tumors: A single institutional experience of 26 cases

Favorite
PATH-44

An Unusual Presentation of a Pediatric Midline H3K27M-Mutant Tumor with Disseminated Craniospinal Leptomeningeal Disease

Favorite
QOLP-01

Outcome Assessment Of Multidisciplinary Brain Tumor Board Meeting Recommendations For Brain Metastasis: Is There A Gap?

Favorite
QOLP-03

Neuro-oncology palliative care survey of physicians in Sub-Saharan Africa

Favorite
QOLP-04

Pilot Study of a Videoconference-Based Psychological Intervention for Family Caregivers of Patients with Malignant Gliomas

Favorite
QOLP-05

Olanzapine for Refractory Chemotherapy-Induced Nausea and Vomiting in Malignant Glioma Patients

Favorite
QOLP-06

Phenomenological exploration of the lived experience of quality of life for patients with glioblastoma and their primary care partners

Favorite
QOLP-07

Health-related quality of life and symptom burden in patients with newly diagnosed glioblastoma treated with bevacizumab beyond progression: a prospective trial

Favorite
QOLP-08

Utilizing stakeholder engagement to develop a mindfulness-based intervention for patients with Glioblastoma (GBM) and their caregivers

Favorite
QOLP-09

Health economic evaluation of low-grade glioma management: a systematic review

Favorite
QOLP-10

Monitoring trends in patient distress in glioblastoma using the PHQ4 questionnaire

Favorite
QOLP-11

Quality of End-of-Life Care in Patients with High Grade Gliomas

Favorite
QOLP-13

Comparison of symptom burden and associated impact on daily life in glioblastoma patients treated with and without Tumor Treating Fields

Favorite
QOLP-14

From symptoms to radiotherapy: a qualitative assessment of patient experience in newly diagnosed high-grade glioma

Favorite
QOLP-16

Efficacy of Scrambler Therapy (Calmare®) For the Treatment of Chronic Chemotherapy-induced Peripheral Neuropathy

Favorite
QOLP-19

Insomnia in brain tumor patients: Assessing needs in neuro-oncology

Favorite
QOLP-20

A feasibility study utilizing mindfulness meditation during concomitant chemoradiation in malignant glioma patients: health-reported quality of life (HRQoL) results

Favorite
QOLP-21

A Preliminary Report on Quality of Life and Sexual Function in Brain Cancer Patients

Favorite
QOLP-23

Phase II randomised placebo-controlled double-blind study of acetazolamide versus placebo for cerebral oedema in recurrent and/or progressive high-grade glioma requiring treatment with dexamethasone

Favorite
QOLP-24

Engaging Patients and Caregivers to Improve the Importance and Quality of Supportive Care Research in Neuro-Oncology

Favorite
QOLP-25

Baseline quality of life burden in patients with central nervous system (CNS) tumours treated with pencil beam proton therapy at India’s first proton therapy centre

Favorite
QOLP-27

Use of the Neuro-QOL Cognitive Function Short-Form as a Tool for Assessing Patient-Perceived Neurocognition Following Radiotherapy

Favorite
QOLP-28

Preoperative sleep disturbance and its association with quality of life in adult brain tumor patients

Favorite
QOLP-29

Information on headache for brain tumor patients on internet –guiding or misleading?

Favorite
QOLP-30

Fear of Cancer Recurrence in Primary Brain Tumor Patients: Do Disease-Related Characteristics Matter?

Favorite
RADT-01

The efficacy and safety of two-staged stereotactic radiosurgery for large posterior fossa metastases: post-treatment volumetric changes in tumor size, peri-tumoral edema, and fourth ventricle

Favorite
RADT-04

Resection cavity failure of melanoma brain metastases when treated with systemic therapy, with or without focal radiotherapy.

Favorite
RADT-05

Clinical Outcomes of Proton Craniospinal Irradiation for Patients with Leptomeningeal Carcinomatosis

Favorite
RADT-06

Volume kinetics following two-session Gamma Knife radiosurgery for large brain metastases (BM)

Favorite
RADT-07

Stereotactic radiosurgery of patients with brain metastases and poor prognosis.

Favorite
RADT-09

Type and timing of systemic therapy use predict survival in patients with brain metastases treated with radiation therapy

Favorite
RADT-10

Survival in Patients fulfilling CCTG CE.7 Eligibility Criteria: Evaluating Initial Stereotactic Radiosurgery for 5-15 Brain Metastases

Favorite
RADT-12

Disease Characteristics in Acute Seizure following Radiotherapy for Brain Metastases

Favorite
RADT-14

Comparison of machine learning algorithms in distinguishing radiation necrosis from progression of brain metastases treated with stereotactic radiosurgery (SRS)

Favorite
RADT-16

Hypofractionated Radiotherapy and Stereotactic Radiosurgery for Vestibular Schwannomas: a Systematic Review and Meta-Analysis

Favorite
RADT-18

Long-term follow-up of patients treated with Gamma Knife® stereotactic radiosurgery (GK-SRS) for vestibular schwannoma (VS)

Favorite
RADT-19

Effects of radiation dose-rate and tumor characteristics on local control and toxicity after radiosurgery for acoustic neuromas

Favorite
RADT-20

Histopathologic findings in malignant peripheral nerve sheath tumor are both prognostic for overall survival and predictive for response to radiation therapy

Favorite
RADT-21

National Practice Patterns and Outcomes of Stereotactic Body Radiotherapy vs. Conventional External Beam Radiotherapy for Spinal Metastases

Favorite
RADT-23

Impact of Reirradiation Utilizing Stereotactic Radiosurgery on Recurrent Glioblastoma

Favorite
RADT-24

High absorbed doses of Rhenium-186 nanoliposomes (RNL) in recurrent GBM: a phase 1 study

Favorite
RADT-25

Evaluating lymphocyte counts in newly diagnosed glioblastoma patients receiving chemoradiation

Favorite
RADT-26

Laser Interstitial Thermal Therapy for Recurrent Glioblastoma: Pooled Analyses of Available Literature

Favorite
RADT-28

Radiation dose-dependent long-term neurocognitive decline in low grade glioma patients: results of a cross-sectional study

Favorite
RADT-31

Patterns of care in the use of adjuvant radiotherapy and chemotherapy in low grade glioma patients in the United States from 2010-2016

Favorite
RADT-33

Radiosurgery versus combination radiosurgery-bevacizumab for the treatment of recurrent high-grade glioma: a systematic review

Favorite
RADT-36

Prospectively Assessed Tumor Control and Toxicity of Benign Intracranial Pathologies Treated with Automated VMAT Radiosurgery – Initial 2 Year Experience with First 100 Patients

Favorite
RADT-37

The Impact of Postoperative Radiation Therapy (PORT) And Extent of Surgery on Clinical Outcomes of Atypical Meningioma (AM): A Meta-Analysis

Favorite
RADT-38

Adjuvant radiotherapy for intracranial atypical and malignant Meningiomas in adult patients

Favorite
RADT-39

68Ga- DOTATATE CT/PET for Gamma Knife Radiosurgery Planning and Target Delineation in Patients with Meningioma

Favorite
RADT-40

Trends in the use of radiation for meningioma across the United States

Favorite
RADT-41

Assessing the role of adjuvant radiation therapy and risk factors for recurrence following gross total resection of atypical meningiomas

Favorite
RADT-42

Adjuvant Radiation Therapy for Subtotally Resected Cerebellar Liponeurocytoma

Favorite
RADT-43

Treatment of Retroperitoneal Leiomyosarcoma Brain Metastases with Stereotactic Radiosurgery

Favorite
RADT-46

Systematic review of radiosensitizers for malignant brain tumors: potential for learning from past failures

Favorite
RADT-47

A multicenter observational study of surgically targeted radiation therapy (STaRT) using implanted Cs-131 seeds in a collagen-based carrier tile in intracranial brain neoplasms - protocol in progress

Favorite
RBIO-03

Heterogeneity of human patient-derived xenografts growth rates responses to the radiated microenvironment

Favorite
RBIO-04

New Therapeutic Delivery Methods for Tumor-Treating Fields for Higher Efficacy

Favorite
RBIO-06

Implementation of human induced pluripotent stem cell derived cerebral organoids to model normal tissue radioresponse

Favorite
RTID-01

Radiosurgery followed by Tumor Treating Fields for brain metastases (1-10) from NSCLC in the phase 3 METIS trial

Favorite
RTID-03

A Phase I Clinical Trial to Evaluate MTD of Perampanel and Memantine in Combination with Standard Chemoradiotherapy for the Treatment of Patients With Newly Diagnosed GBM –A Study Design

Favorite
RTID-04

A randomized phase II trial to compare the efficacy of standard versus combination therapy (Perampanel, Memantine plus standard) in the treatment of patients with newly diagnosed GBM-A Study Design

Favorite
RTID-05

INDIGO: A global, randomized, double-blind, phase 3 study of vorasidenib (AG-881) vs placebo in patients with residual/recurrent grade II glioma with an isocitrate dehydrogenase 1/2 (IDH1/2) mutation

Favorite
RTID-06

Enhancing Tumor Treating Fields therapy for recurrent glioblastoma with targeted and individualized skull remodeling surgery. A multi-center randomized phase 2 trial

Favorite
RTID-07

Human Placental hematopoietic Stem Cell Derived Natural Killer Cells (CYNK-001) for Treatment of Recurrent Glioblastoma

Favorite
RTID-08

A Phase 1/2 study of Selinexor in combination with standard of care therapy for newly diagnosed or recurrent Glioblastoma (ndGBM or rGBM)

Favorite
RTID-09

A Randomized, Double-Blinded, Phase 3 Study of Enzastaurin Added to Temozolomide During and Following Radiation Therapy in Newly Diagnosed Glioblastoma Patients Who Possess the Novel Biomarker, DGM1

Favorite
RTID-10

Surgeons Trial Of Prophylaxis for Epilepsy in seizure naïve patients with Meningioma: a randomized controlled trial (STOP ‘EM)

Favorite
RTID-11

GBM AGILE: A global, phase 2/3 adaptive platform trial to evaluate multiple regimens in newly diagnosed and recurrent glioblastoma

Favorite
RTID-12

Phase 2 trial of Tumor Treating Fields (TTFields) plus radiation therapy (RT) plus temozolamide (TMZ) compared to RT plus temozolomide in newly diagnosed glioblastoma (ndGBM)

Favorite
STEM-02

In vivo phage display identifies peptide targeting N-cadherin on glioma stem cells

Favorite
STEM-03

WAVE1 Knockdown Enhances the Antitumor Efficacy in Primary Glioblastoma Neurospheres

Favorite
STEM-04

Platelets Drive Glioblastoma Oncogenesis by Enhancing the Glioma Stem Cell Phenotype

Favorite
STEM-05

Single Cell Sequencing Characterizes Spatial and Temporal Relationships of Enhancing and Non-Enhancing Regions in High-Grade Glioma

Favorite
STEM-06

The role of IFITMs in maintaining glioma stem cells

Favorite
STEM-08

Platelets drives glioblastoma oncogenesis by enhancing the glioma stem cell phenotype

Favorite
STEM-09

Intrinsic interferon signaling regulates the cell death of glioblastoma stem cells

Favorite
STEM-10

Long-lasting Tumor Treating Fields (TTFields) stimulation of glioblastoma primary culture damages preferentially fully differentiated cancer cells

Favorite
STEM-11

Interrogating intratumoral transcriptomic heterogeneity and plasticity as resistance mechanisms in Glioblastoma

Favorite
STEM-13

Functional characterization of the ZFHX4-CHD4 interaction in glioblastoma cancer stem cells

Favorite
STEM-14

Glioblastoma stem cell targeting chimeric antigen receptor T cells modified using phage display isolated peptides

Favorite
STEM-15

Small but Fierce: The Role of Extracellular Vesicles in Mesenchymal Transition and Therapeutic Resistance in Glioblastoma

Favorite
STEM-17

Not all GBM stem cells are equal: implications for research and therapy

Favorite
STEM-19

The isolation and identification of Glioma Stem Cells and Mesenchymal Stem Cells From Human Glioma Specimens

Favorite
STEM-20

A Cancer Stem Cell-Selective Apoptosis-Inducing Small Molecule For The Treatment Of GBM

Favorite
STEM-21

Clinical relevance of cancer stem cell cytotoxicity assay in guiding treatment for glioblastoma

Favorite
STEM-22

Targeting KIF11 to Radiosensitize Glioblastoma

Favorite
STEM-23

Inhibiting protein phosphatase 2A increases the antitumor effect of protein arginine methyltransferase 5 inhibition in models of glioblastoma

Favorite
STEM-24

Radiation-induced extracellular vesicle (EV) release of miR-603 promotes IGF1-mediated stem call state in glioblastomas

Favorite
STEM-25

Differential regulation of glioma stem-cell marker nestin and CD24 in IDH-mutant glioma

Favorite
STEM-26

Small molecule drug CBL0137 inhibits the FACT complex and sensitizes glioblastoma cancer stem cells to radiotherapy

Favorite
STEM-27

miR-10b-5p modulates 5hmC expression and the stem-like phenotype in GBM

Favorite
SURG-04

Salvage resection of recurrent previously-irradiated brain metastases: clinical and radiographic outcomes

Favorite
SURG-05

Ideal treatment regimen for patients with ≥1 brain metastasis from primary non-small-cell lung cancer – a systematic review and network meta-analysis

Favorite
SURG-06

Management of hydrocephalus in adult patients with brain metastases

Favorite
SURG-08

Awake craniotomy with brain mapping for diffuse low-grade glioma: case report of institutional experience in overcoming hurdles in a low-resource setting

Favorite
SURG-10

Prognostic importance of the extent of resection in IDH-wild type grade II astrocytomas according to pTERT mutation.

Favorite
SURG-11

Neoadjuvant chemotherapy for diffuse gliomas: A feasible option?

Favorite
SURG-12

Predictors of survival and utility of intraoperative MRI for resection of grade II astrocytomas and oligodendrogliomas: a multicenter analysis

Favorite
SURG-15

A novel risk model to define the relative benefit of maximal extent of resection within prognostic groups in newly diagnosed diffuse low-grade glioma

Favorite
SURG-16

Predictors of Local Control Following Laser Interstitial Thermal Therapy for Glial Tumors.

Favorite
SURG-19

Evaluation of Serum Neuron Specific Enolase, Interferon-alpha, and Interferon-gamma in Response to Laser Ablation of High Grade Gliomas

Favorite
SURG-23

Reoperation in Molecular Subtypes of Recurrent Glioblastoma

Favorite
SURG-24

Repeat Convection-Enhanced Delivery for Diffuse Intrinsic Pontine Glioma

Favorite
SURG-27

Treating Hydrocephalus in Diffuse Midline Gliomas with an H3 K27M Mutation

Favorite
SURG-28

Presentation of a posterior fossa tumor at a hospital in western Jamaica

Favorite
SURG-29

Clinical factors associated with recurrence in atypical meningioma: retrospective analysis of 99 patients in two institutes

Favorite
SURG-31

Surgical Outcome Analyses on 244 Central Nervous System Hemangioblastoma

Favorite
SURG-32

Differences in surgical outcome between von Hippel-Lindau disease related and sporadic hemangioblastomas in the central nervous system

Favorite
SURG-33

Role of Surgery in Treating Epstein-Barr Virus-Associated Smooth Muscle Tumor (EBV-SMT) with Central Nervous System Invasion: A Systemic Review

Favorite
SURG-34

Multidisciplinary management of a patient with optic pathway-hypothalamic langerhans cell histiocytosis: a case report

Favorite
SURG-35

Intracranial myxoid mesenchymal tumor with EWSR1-ATF1 gene fusion

Favorite
SURG-37

Systematic review of Gamma-knife Radiosurgery and Microsurgical Resection for Brainstem Cavernous Malformations.

Favorite
SURG-38

Seizure outcome after epilepsy surgery in children with brain tumors

Favorite
SURG-40

Surgical resections in Broca’s Area do not lead to Broca’s aphasia

Favorite
SURG-41

Blood-brain barrier disruption with high-frequency electroporation in vivo: a preliminary investigation demonstrating the effects of varied pulse widths and intra-phase delays

Favorite
SURG-43

Applications and restriction of 980nm diode laser for brain tumor microsurgery - a pioneer case series and a critical review

Favorite
TAMI-02

Alterations in C-X3-C motif chemokine receptor 1 (CX3CR1) expression influence microglial and macrophage response in different steps of cerebral metastasis formation

Favorite
TAMI-03

Identification of novel drivers of lung-to-brain metastasis through in vivo functional genomics

Favorite
TAMI-04

Tumor Treating Fields (TTFields) hinder glioma cell motility through regulation of microtubule and actin dynamics

Favorite
TAMI-06

Preclinical models reveal brain-microenvironment specific metabolic dependencies in glioblastoma

Favorite
TAMI-09

Energy metabolism and therapeutic T cell efficacy in the glioblastoma microenvironment

Favorite
TAMI-10

Circulating angiogenic cells (CACs) in glioblastoma: towards defining crucial functional differences in CAC-induced neoplastic versus reactive neovascularization

Favorite
TAMI-11

Impact of oHSV activated NOTCH signaling in tumor microenvironment, and its impact on anti-tumor immunity

Favorite
TAMI-14

Nanoparticle delivery of PD-L1 CRISPR/Cas9 plasmid DNA for anti-Glioblastoma immunotherapy

Favorite
TAMI-15

The effect of interstitial fluid flow and astrocytes / microglia on invasion, proliferation and stemness of patient-derived glioma stem cells

Favorite
TAMI-16

Biomaterial matrices to study glioblastoma invasion

Favorite
TAMI-17

Relationship between iron metabolism, immune cell infiltration and sex-based survival differences in gliomas

Favorite
TAMI-18

Single-cell sequencing and genetic labeling to characterize hypoxic GBM cells in their microenvironment

Favorite
TAMI-22

Variation among intact tissue samples reveals the core transcriptional identities of cell types in the glioma microenvironment

Favorite
TAMI-23

Neutrophil-triggered ferroptosis promotes tumor necrosis in glioblastoma progression

Favorite
TAMI-24

Behavior of glioblastoma stem-like cells with known IDH1 status in cerebral organoids

Favorite
TAMI-29

Multifactorial upregulation of ID1 drives DIPG invasiveness and is therapeutically targetable

Favorite
TAMI-34

Sex-specific metabolic adaptations to the ketogenic diet in a mouse model of glioblastoma

Favorite
TAMI-36

Connexin 43 blockade inhibits proliferation in IDH1-mutant glioma cells

Favorite
TAMI-38

Cysteine-promoting compounds induce mitochondrial toxicity in glioblastoma through altered pyruvate and serine metabolism

Favorite
TAMI-39

Age-dependent phenotypic conversion from neuronal activity to neuro-inflammation in glioblastoma progression

Favorite
TAMI-40

Tumor microbiome and Glioblastoma (GBM)

Favorite
TAMI-43

Impact of sex and radiation on iron trafficking in bone marrow derived macrophages

Favorite
TAMI-45

Phenogenomic characterization of immunomodulatory purinergic signaling in glioblastoma

Favorite
TAMI-47

Evaluation of the effect of microenvironmental stresses on glioma stemness in vitro and ex vivo.

Favorite
TAMI-48

Engraftment phenotypes in preclinical model systems reveal a functional subgroup of patient tumors dependent on the brain tumor microenvironment for growth

Favorite
TAMI-49

The Alternative Splicing Factor MBNL1 Inhibits Glioblastoma Tumor Initiation and Progression by Reducing Hypoxia-induced Stemness

Favorite
TAMI-50

Chitinase-3-like-1 protein binding complexes regulate immune suppression in glioblastoma

Favorite
TAMI-51

Identifying new Tumor Microenvironment (TME) contexts of vulnerability in Glioblastoma

Favorite
TAMI-54

The Presence of Immune Cell Infiltrates in the Tissue Microenvironment of High-Grade Gliomas and their Association with Overall Survival

Favorite
TAMI-55

The evolutionary enigma of fatty acid desaturation in Glioblastoma

Favorite
TAMI-58

A novel role for REST in the control of the medulloblastoma microenvironment

Favorite
TAMI-62

Angiogenesis inhibitors strongly synergize with therapeutics targeting tumor metabolism

Favorite
TAMI-63

Glioblastoma associated mesenchymal stem like cells (G-MSC) which infiltrate tumors in human and mouse are strongly associated with immunosuppression

Favorite
TAMI-64

Physical stresses in brain tumors

Favorite
TMOD-03

Pan-cancer analysis of orthotopic patient derived xenografts from brain metastases

Favorite
TMOD-05

Extracranial tumors influence intracranial response to immune checkpoint inhibitors in pre-clinical models of melanoma brain metastasis

Favorite
TMOD-06

Malignant transformation of plexiform neurofibromas in an Nf1 mutant mouse model of spinal irradiation

Favorite
TMOD-09

Glioblastoma biophysical growth estimation using deep learning-based regression

Favorite
TMOD-10

Effect of brain tumorigenesis on cerebral cortical functional connectivity in the mouse

Favorite
TMOD-12

Establishing a clinically relevant model of mesenchymal glioblastoma (GBM) to study response to standard of care treatment and immune checkpoint inhibition (ICI).

Favorite
TMOD-13

Research resources for oligodendroglioma now available to research community

Favorite
TMOD-14

Creation of a Genetically Engineered Mouse Model of Anaplastic Astrocytoma Driven by the IDH1-R132H Oncogene

Favorite
TMOD-15

Efficacy of the MDM2 inhibitor KRT-232 in glioblastoma patient-derived xenograft models

Favorite
TMOD-17

Oncolytic poliovirus as a probe for mechanisms of immune resistance in glioblastoma

Favorite
TMOD-18

Targeting the PI3K/Akt pathway in MYCN amplified high grade gliomas

Favorite
TMOD-20

A swine model of glioblastoma induced by somatic gene modification

Favorite
TMOD-24

Generation and characterization of a novel transgenic IDO reporter mouse for IDO posttranslational modification analysis in situ

Favorite
TMOD-25

In vivo model of treatment-resistant glioblastoma highlights sex differences in survival

Favorite
TMOD-26

Establishing a patient-derived, in-vitro organotypic slice culture model of GBM

Favorite
TMOD-27

Efficacy of soluble panobinostat (MTX110) in preclinical models of adult glioblastoma

Favorite
TMOD-29

Establishment of patient-derived xenografts from rare primary brain tumors

Favorite
TMOD-31

Novel Genetic Characterization of Murine Medulloblastoma Cell Lines

Favorite
TMOD-33

The Role of BAFF-R signaling in the growth of primary central nervous system lymphoma

Favorite
TMOD-37

In vivo compression and imaging for causal studies of mechanical forces in the brain

Favorite